One Month Degarelix/Comparator Treatment for Prostate Cancer in Chinese Population
NCT ID: NCT01744366
Last Updated: 2015-06-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
285 participants
INTERVENTIONAL
2013-01-31
2015-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
An Extension Long-term Safety and Tolerability Trial of Degarelix in Chinese Patients With Prostate Cancer
NCT02015871
A Study of Degarelix in Taiwanese Patients With Prostate Cancer
NCT01220869
A Trial of Degarelix in Patients With Prostate Cancer
NCT00946920
Pharmacokinetics of Degarelix in Chinese Patients With Prostate Cancer
NCT02468284
Efficacy and Safety of Degarelix One Month Dosing Regimen in Korean Patients With Prostate Cancer
NCT01071915
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Degarelix
Degarelix 240/80 mg
Degarelix
Goserelin
Goserelin 3.6 mg
Goserelin
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Degarelix
Goserelin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Adenocarcinoma of the prostate
* Relevant disease status based on lab values and as judged by the physician
* Life expectancy of at least a year
Exclusion Criteria
* Considered to be candidate for curative therapy
* Risk or history of any serious or significant health condition
* Has received an investigational drug within the last 28 days and no previous treatment with degarelix
18 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ferring Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Development Support
Role: STUDY_DIRECTOR
Ferring Pharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cancer Institute & Hospital. Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
Affiliated Southwest Hospital of 3rd Military Medical University of People's Liberation Army
Chongqing, Chongqing Municipality, China
1st Afilliated Hospital of Guangzhou Medical College
Guangzhou, Guangdong, China
Renmin Hospital of Wuhan University
Wuhan, Hubei, China
2nd.Affiliated Hospital of Xi'an Jiaotong University College of Medicine
Xi’an, Shanxi, China
1st Hospital Affiliated to Zhejiang University Medical School
Hangzhou, Zhejiang, China
Beijing Hospital of Ministry of Health
Beijing, , China
Peking Union Hospital
Beijing, , China
Peking University 3rd Hospital
Beijing, , China
Peking University People's Hospital
Beijing, , China
1st Hospital of Jilin University
Changchun, , China
Hunan Cancer Hospital
Changsha, , China
Hunan Province People's Hospital
Changsha, , China
People's Hospital of Sichuan
Chengdu, , China
2nd Hospital Affiliated to Zhejiang University Medical School
Hangzhou, , China
1st Hospital of Lanzhou University
Lanzhou, , China
1st Affiliated Hospital of Nanchang University
Nanchang, , China
1st Affiliated Hospital of Nanjing Medical University
Nanjing, , China
Drum Tower Hospital Affiliated to Nanjing University Medical School
Nanjing, , China
Fudan University Shanghai Cancer Center
Shanghai, , China
Huashan Hospital of Fudan University
Shanghai, , China
Shanghai 5th People's Hospital affilicated to Fudan University
Shanghai, , China
Shanghai Changhai Hospital
Shanghai, , China
1st Hospital Affiliated to China Medical University
Shenyang, , China
2nd Hospital Affiliated to Suzhou University
Suzhou, , China
2nd Hospital of Tianjin Medical University
Tianjin, , China
Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology
Wuhan, , China
Zhongnan Hospital of Wuhan University
Wuhan, , China
1st People's Hospital of Wuxi
Wuxi, , China
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Zengerling F, Jakob JJ, Schmidt S, Meerpohl JJ, Blumle A, Schmucker C, Mayer B, Kunath F. Degarelix for treating advanced hormone-sensitive prostate cancer. Cochrane Database Syst Rev. 2021 Aug 5;8(8):CD012548. doi: 10.1002/14651858.CD012548.pub2.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
000006
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.